1. Scrip

Sanofi Chief Issues Warning To Innovation-Unfriendly EU

 
• By Kevin Grogan

Paul Hudson told Scrip that while the EU's prioritization on matters such as boosting hydrogen use and electric car batteries was laudable, delivery of healthcare and the innovation associated with it should be "a strategic imperative."

Paul Hudson
Paul Hudson • Source: Sanofi

Sanofi CEO Paul Hudson has again spoken out about plans to overhaul EU pharmaceutical legislation and its negative impact on innovative R&D firms, saying further obstacles to market access will hamper the continent's efforts to compete with the US and China.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.